open access

Vol 11, No 5 (2015)
Review paper
Published online: 2016-02-17
Get Citation

Anti-proliferative effect of somatostatin analogues in gastroenteropancreatic neuroendocrine tumours

Agnieszka Kolasińska-Ćwikła
Oncol Clin Pract 2015;11(5):272-275.

open access

Vol 11, No 5 (2015)
REVIEW ARTICLES
Published online: 2016-02-17

Abstract

Gastroenteropancreatic neuroendocrine tumours (GEP NET) belong to a heterogeneous group of rare tumours. Most NETs of the gastrointestinal tract are non-functioning and therefore are diagnosed at an advanced stage, which impedes radical surgery. Overexpression of somatostatin receptors (SSTR) can be found in most GEP-NETs. Somatostatin analogues play a major role in therapy of hormonally active NETs. These agents also have an anti-proliferative effect, interacting directly with membrane receptors on tumour cells or by indirect inhibition of growth factors, angiogenesis, induction of apoptosis, or their effect on the immune system. The anti-proliferative effect of octreotide LAR was demonstrated in the phase III randomised study PROMID, which included 84 treatment-naive patients with disseminated well differentiated NETs of midgut or unknown origin. The anti-tumour effect of octreotide LAR was observed irrespective of tumour functional status. Additionally, a retrospective study was presented at the ASCO meeting in 2014, showing a therapeutic effect of octreotide LAR of even longer duration than in the PROMID study. Authors of the report identified also favourable predictive factors for octreotide LAR therapy. The anti-proliferative effect of lanreotide Autogel® was demonstrated in the CLARINET study, which included 204 patients with non-functioning GEP-NETs, differentiation grade of G1 or G2, proliferation index Ki-67 up to 10%, locally inoperable, or metastasised. Results of the study showed decreased relative risk of disease progression by 53% in patients with GEP-NETs located in the pancreas, midgut, or of unknown origin.

Abstract

Gastroenteropancreatic neuroendocrine tumours (GEP NET) belong to a heterogeneous group of rare tumours. Most NETs of the gastrointestinal tract are non-functioning and therefore are diagnosed at an advanced stage, which impedes radical surgery. Overexpression of somatostatin receptors (SSTR) can be found in most GEP-NETs. Somatostatin analogues play a major role in therapy of hormonally active NETs. These agents also have an anti-proliferative effect, interacting directly with membrane receptors on tumour cells or by indirect inhibition of growth factors, angiogenesis, induction of apoptosis, or their effect on the immune system. The anti-proliferative effect of octreotide LAR was demonstrated in the phase III randomised study PROMID, which included 84 treatment-naive patients with disseminated well differentiated NETs of midgut or unknown origin. The anti-tumour effect of octreotide LAR was observed irrespective of tumour functional status. Additionally, a retrospective study was presented at the ASCO meeting in 2014, showing a therapeutic effect of octreotide LAR of even longer duration than in the PROMID study. Authors of the report identified also favourable predictive factors for octreotide LAR therapy. The anti-proliferative effect of lanreotide Autogel® was demonstrated in the CLARINET study, which included 204 patients with non-functioning GEP-NETs, differentiation grade of G1 or G2, proliferation index Ki-67 up to 10%, locally inoperable, or metastasised. Results of the study showed decreased relative risk of disease progression by 53% in patients with GEP-NETs located in the pancreas, midgut, or of unknown origin.

Get Citation

Keywords

neuroendocrine tumours, somatostatin analogues, octreotide LAR, lanreotide Autogel®

About this article
Title

Anti-proliferative effect of somatostatin analogues in gastroenteropancreatic neuroendocrine tumours

Journal

Oncology in Clinical Practice

Issue

Vol 11, No 5 (2015)

Article type

Review paper

Pages

272-275

Published online

2016-02-17

Bibliographic record

Oncol Clin Pract 2015;11(5):272-275.

Keywords

neuroendocrine tumours
somatostatin analogues
octreotide LAR
lanreotide Autogel®

Authors

Agnieszka Kolasińska-Ćwikła

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl